Evotec has announced that its Seattle-based subsidiary, Just – Evotec Biologics, has received a new grant from the Gates Foundation to advance global access to biotherapeutics using its cutting-edge molecular design platform, J.MD.

 

The grant continues the foundation’s support for select grantees focused on improving the developability and lowering the cost of monoclonal antibodies, making life-saving therapies more affordable and accessible in low- and middle-income countries.

 

Under the terms of the award, Just – Evotec Biologics will use its J.MD Molecular Design service, a core component of the J.DESIGN platform, to optimize the development of biotherapeutics from the earliest stages. 

 

The platform integrates advanced computational tools with high-throughput methodologies to ensure manufacturability, stability, and efficacy—critical factors for reducing costs, expanding global access, and minimizing risks like immunogenicity and instability.

 

The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats. This extends a partnership with the Gates Foundation that began in 2014, which has already delivered multiple cGMP manufacturing campaigns for RSV, Malaria, and HIV monoclonal antibodies.

 

Dr Linda Zuckerman, EVP and Global Head of Just – Evotec Biologics, said: "We are thrilled to receive this new grant from the Gates Foundation which will strengthen our commitment to reducing the cost of biologics development to expand global access. 

 

"By leveraging our J.DESIGN platform and innovative molecular design tools, we look forward to supporting the foundation in driving impactful solutions across multiple disease areas and continuing to deliver therapies where they are needed most.”

 

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, added: "We are proud to continue our collaboration with the foundation through this new grant which enables us to harness Just – Evotec Biologics’ advanced platforms and scientific expertise to support the broader research ecosystem. This partnership strengthens our shared mission to accelerate the development of biotherapeutics that address urgent and unmet medical needs.”